А.Т. Быков, Ю.М. Амбалов, Т.Н. Маляренко
УО «Кубанский государственный медицинский университет», УО «Ростовский государственный медицинский университет»
В обзоре продемонстрировано, что мировая литература последних лет обогатилась новыми знаниями о роли кишечной микробиоты в развитии неалкогольных хронических заболеваний печени и защите от них. Установлено, что микробиота необходима для поддержания гомеостаза печени при её хронических повреждениях, а низкий базальный уровень бактериальных продуктов делает невозможным включение механизмов защиты печени от токсических факторов.
ключевые слова: неалкогольные хронические заболевания печени, ось ‘кишечник-печень’, кишечная микробиота, дисбиоз, бактериальная транслокация, превентивные стратегии
Liver diseases: pathogenetic and hepatoprotective role of gut microbiota
A.T. Bykov, Yu.M. Ambalov, T.N. Malyarenko
The review demonstrates that the world literature of recent years has been enriched with new knowledge about the role of intestinal microbiota in the development of non-alcoholic chronic liver diseases and protection from them. It has been established, that a microbiota is necessary to maintain the liver homeostasis during its damage, and a low basal level of bacterial products makes it impossible to incorporate protective mechanisms against toxic factors.
keywords: nonalcoholic chronic liver diseases, gut-liver axis, gut microbiota, dysbiosis, bacterial translocation, preventive strategies
1. Быков А.Т., Шапошников А.В., Маляренко Т.Н. Микробиота кишечника: вклад в здо-ровье и профилактику заболеваний человека // Медицинский журнал. ‒ 2016. ‒ № 4. ‒ С. 16-26.
2. Abdou R.M., Zhu L., Baker R.D., et al. Gut microbiota of nonalcoholic fatty liver disease // Dig. Dis. Sci. – 2016. – Vol. 61. – P. 1268-1281.
3. Archarya C., Bajaj J.S. Gut microbiota and complications of liver disease // Gastroenterol. Clin. North Am. – 2017 Mar. – Vol. 46. – No. 1. – P. 155-169.
4. Bajaj J.S., Heuman d.M., Hylemon P.B., et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications // J. Hepatol. – 2014. – Vol. 60. – P. 940-947.
5. Bellot P., Francѐs R., Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications // Liver Intern. – 2013. – Vol. 33. – P. 31-39.
6. Benten D., Wiest R. Gut microbiome and intestinal barrier failure – “Achilles heel” in hepatology? // J. Hepatol. – 2012. – Vol. 56. – P. 1221-1223.
7. Bhat M., Arendt B.M., Bhat V., et al. Implication of the intestinal microbiome in complications of cirrhosis // World J. Hepatol. – 2016 Sep. 28. – Vol. 8. – No. 27. – P. 1128-1136.
8. Boursier J., Diehl A.M. Implication of gut microbiota in nonalcoholic fatty liver disease // PLoS Pathol. ‒ 2015. ‒ Vol. 11. ‒ No. 1. ‒ e1004559.
9. Bressa C., Bailѐn-Andrino M., Pѐrez-Santiago J., et al. Differences in gut microbiota profile between women with active lifestyle and sedentary women // PLoS ONE. – 2017. – Vol. 12. – No. 2. – e0171352.
10. Cani P.D., Everard A. Talking microbes: when gut bacteria interact with diet and host organs // Mol. Nutr. Res. – 2016. – Vol. 60. – P. 58-66.
11. Compare D., Coccoli P., Rocco A., et al. Gut-liver axis: the impact of gut microbiota on non alcoholic fatty liver disease // Nutr., Metab., Cardiovasc. Diseases. – June 2012. – Vol. 22. – Issue 6. – P. 471-476.
12. Dao M.C., Everard A., Aron-Wisnewsky J., et al. Akkermansia muciniphila and improved metabolic health during dietary intervention in obesity: relationship with gut microbiome richness and ecology // Gut. – 2016. – Vol. 65. – P. 426-436.
13. Everard A., Belzer C., Geurts L., et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity // Proc. Natl. Acad. Sci. USA. – 2013. – Vol. 110. – P. 9066-9071.
14. Fukui H. Gut-liver axis in liver cirrhosis: how to manage leaky gut and endoxemia // World J. Gastroenterol. – 2015. – Vol. 7. – P. 425-442.
15. Giannelli V., Di Gregorio V., Iebba V., et al. Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis // World J. Gastroenterol. – 2014 Dec. 7. – Vol. 20(45). – P. 16795-16810.
16. Goel A., Gupta M., Aggarwal R. Gut microbiota and liver disease // J. Gastroenterol. Hepatol. – 2014. – Vol. 29. – P. 1139-1148.
17. Kesar V., Odin J.A. Toll-like receptors and liver disease // Liver Int. – 2014. – Vol. 34. – P. 184-196.
18. Kummen M., Holm K., Anmarkud J.A., et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy control // Gut. – 2017 April. – Vol. 66. – No. 4. – P. 611-619.
19. Leung C., Rivera L., Furness J.B., Angus P.W. The role of the gut microbiota in NAFLD // Nature Rev. Gastroenterol. Hepatol.: Nature Research. – 2016. – Vol. 13. – P. 412-416.
20. Li K., Bihan M., Methѐ B.A. Analyses of the stability and core taxonomic memberships of human microbiome // PLoS One. – 2013. – Vol. 8. – e63139.
21. Lin L., Zhang J. Role of intestinal microbiota and metabolites on gut homeostasis and human diseases // BMC Immunology. – 2017. – Vol. 18. – No. 2. – 25 p.
22. Llorente C., Schnabl B. The gut microbiota and liver disease // Cel. Molec. Gastroenterol. Hepatol. 2015. – No. 1. – P. 275-284.
23. Loomba R., Sanyal A.J. The global NAFLD epidemic // Nat. Rev. Gastroenterol. Hepatol. – 2013. – Vol. 10. – P. 686-690.
24. Macnaughtan J., Jalan R. Clinical and pathophysiological consequences of alterations in the microbiome in cirrhosis // Am. J. Gastroenterol. – 2015. – Vol. 110. – P. 1399-1410.
25. Malaguarnera M., Vacante M., Antic T., et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non-alcoholic steatohepatitis //Dig. Dis. Sci. – 2012. – Vol. 57. – P. 545-553.
26. Mazagova M., Wang L., Anfora A.T., et al. Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice // FASEB J. – 2015. – Vol. 29. – P. 1043-1055.
27. Minemura M., Shimizu Y. Gut microbiota and liver diseases // World J. Gastroenterol. – 2015. – Vol. 21. – P. 1691-1702.
28. Nakamoto N., Schnabl B. Does the intestinal microbiota explain differences in the epidemiology of liver disease between East and West? // Inflamm. Intest. Dis. ‒ 2016. – Vol. 1. ‒ P. 3-8.
29. Nakayama J., Watanabe K., Jiang J., et al. Diversity in gut bacterial community of school-age children in Asia // Sci. Report. – 2015. – Vol. 5. – P. 8397.
30. Paolella G., Mandato C., Pierri L., et al. Gut-liver axis and probiotics: their role in non-alcogolic fatty liver disease // World J. Gastroenterol. – 2014 Nov. 14. – Vol. 20. – No. 42. – P. 15518-15531.
31. Pedersen H.K., Gudmundsdottir V., Nielsen H.B., et al. Human gut microbes impact host serum metabolome and insulin sensitivity // Nature. – 2016. – Vol. 535. – P. 376-378.
32. Ridlon J.M., Kang D.J., Hylemon P.B., et al. Bile acids and the gut microbiome // Curr. Opin. Gastroenterol. – 2014. – Vol. 30. – P. 332-338.
33. Sabino J., Vieira-Silva S., Machiels K., et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD // Gut. – 2016. – Vol. 65. – P. 1681-1689.
34. Schnabl B., Brenner D.A. Interactions between intestinal microbiome and liver diseases. - Gastroenterology. – 2014. – Vol. 146. – P. 1513-1524.
35. Sipeki N., Antal-Szalmas P., Lakatos P.L., Papp M. Immune dysfunction in cirrhosis // World J. Gastroenterol. – 2014. – Vol. 20. – P. 2564-2577.
36. Tilg H., Cani P.D., Mayer E.A. Gut microbiome and liver diseases // Gut. – 2016 Oct. 08. – Vol. 65. No. 12. – P. 2035-2044.
37. Torres J., Bao X., Goel A., et al. The features of mucosa-associated microbiota in primary sclerosing cholangitis // Aliment. Pharmacol. Ther. – 2016. – Vol. 46. – P. 790-801.
38. Usami M., Miyoshi M., Yamashita H. Gut microbiota and host metabolism in liver cirrhosis // World J. Gastroenterol. – 2015 Nov. 7. – Vol. 21. – No. 41. – P. 11597-11608.
39. Wiest R. The gut microbiome and cirrhosis: basic aspects. In: de Franchis R. (ed). Portal Hypertension VI. Springer Intern. Publishing. Switzerland. – 2016. – Chapter 18. – P. 139-168.
40. Xiao J., Tipoe G.L. Inflammasomes in non-alcoholic fatty liver disease // Fronty. Biosci. (Landmark Ed.). – 2016. – Vol. 21. – P. 683-695.
Формат файла: pdf (299.45 Кб)